Company Overview and News
I’ve been relatively skeptical toward Alphabet Inc (NASDAQ:GOOGL, NASDAQ:GOOG) stock for some time now, and as such have missed out on the big run in GOOG stock. While Alphabet stock has been mostly range-bound since late October, it has made some progress. At the least, $1,000 looks like support for GOOG, instead of the resistance that level offered last year.
FB UL PG AMZN GOOGL UN UNLYF ULVR CSCO MSFT GOOG UNLNF
Making its debut on 05/07/2014, smart beta exchange traded fund WisdomTree International Hedged Quality Dividend Growth Fund (IHDG - Free Report) provides investors broad exposure to the Broad Developed World ETFs category of the U.S. equity market.
HD RHHVF UL UN UNLYF ULVR RHHBY EFA UNLNF IEFA RHHBF
The first quarter of 2018 has been solid regarding profits. They grew by almost 26% — the best Q1 return in eight years. Unfortunately, investors aren’t buying any of the good news, and that’s especially true of consumer stocks, which are getting hammered year to date.
BUD POOL DECK PG UL UN UNLYF ULVR RL THI UNLNF LW NKE KHC CAG
The top three 13F stakes are Berkshire Hathaway, MasterCard, and Nestle and they add up to one-third of the portfolio.
WFCNP PM CCV ULVR WFC.PRL AXP CCZ BATS WFC.PRJ 4162 RI UNLNF CFRHF WFC.PRT JCDXY WFC.PRR WFC.PRQ WFC.PRP WFC.PRO WFC.PRN WFC.PRY WFC.PRX WFC.PRW CMCSK DEO WFC.PRV MO WFC WFC.WS BUD UL UN SWGAF UNLYF CMCSA MA BRK.A V HEIO SWGAY SWGNF CFRUY CCV.CL BFA MLM JCDXF
Law firm Latham & Watkins closed a deal to take 407,000 square feet at the former Time & Life Building, now called 1271 Avenue of the Americas.
MGM HCN FOX WU UL UN UNLYF ULVR WELL.PRI HCN.PRJ CHKP UNLNF AON HCN.PRI MDT EMN.WS HRL CBG EMN KTN WELL ACN FOXA CBRE
This article is part of a series that provides an ongoing analysis of the changes made to Yacktman's 13F stock portfolio on a quarterly basis. It is based on Yacktman Asset Management's regulatory 13F Form filed on 05/09/2018. Please visit our Tracking Yacktman Asset Management series to get an idea of his investment philosophy and our previous update for the fund's moves during Q4 2017.
ATHTF SYY XOM ULVR AVP RDI CHRW UNLNF HPE UHAL VIAB SYK CSCO CMCSK ABBV MMM CRMT MO FOX STT GLW NWS NWSA UNLYF INFY CTSH BRK.A JNJ BK MSFT ABBV CLX FOXA ESRX WFCNP PM MTSI PG STT.PRC CCV STT.PRE STT.PRD STT.PRG WFC.PRL CCZ WFC.PRJ USB COP BAC WFC.PRT GS WFC.PRR OTEL RDIB WFC.PRQ PM WFC.PRP NWS WFC.PRO WFC.PRN KO WFC.PRY WFC.PRX WFC.PRW ORCL DIS WFC.PRV WFC WFC.WS GJV UL UN CMCSA ANTM PEP CCV.CL OCLCF HPQ ANTX
Starbucks Corporation (NASDAQ:SBUX) will get $7.15 billion upfront in cash from Nestle S A/S ADR (OTCMKTS:NSRGY) for the rights to sell Starbucks coffee products in retail and food-service channels.
UL UN UNLYF ULVR SBUX UNLNF
Weaker rating: A Moody’s sign is displayed at the company’s corporate headquarters in New York. Moody’s calculates that almost 36 of US junk-rated companies are rated in B’s lowest level or are already rated C, the riskiest grouping. — Reuters
UL UN UNLYF ULVR UNLNF
Last year, it was pretty tough to lose money in the equities markets. But unfortunately, things are much different this year. If anything, it’s now hard to find any kind of investment that works!
IBM PM BUD PG UL CELGZ UNLYF ULVR UN TWX NFLX TWC UNLNF T CELG MO
2018-06-22 - Asif
Overview Cascadian Therapeutics is a clinical-stage biopharmaceutical company focused on the development of therapeutic products for the treatment of cancer. The company's goal is to develop and commercialize novel targeted compounds that have the potential to improve the lives and outcomes of cancer patients. The company's lead clinical-stage product candidate is tucatinib, an oral, HER2-selective small molecule tyrosine kinase inhibitor. The company's pipeline also includes two preclinical-stage product candidates: CASC-578, a Chk1 kinase inhibitor, and CASC-674, an antibody program against an immuno-oncology target known as TIGIT. 2018 Merger Agreement On January 30, 2018, the company entered into an Agreement and Plan of Merger (the Merger Agreement) with Seattle Genetics, Inc., a Delaware corporation (Seattle Genetics), and Valley Acquisition Sub, Inc., a Delaware corporation and a wholly owned subsidiary of Seattle Genetics (Merger Sub). Pursuant to the Merger ...
2018-06-22 - Asif
Business Overview The Corporation is a Delaware corporation, a bank holding company (BHC) and a financial holding company. When used in this report, “the Corporation” may refer to Bank of America Corporation individually, Bank of America Corporation and its subsidiaries, or certain of Bank of America Corporation’s subsidiaries or affiliates. The company's principal executive offices are located in Charlotte, North Carolina. Through its banking and various nonbank subsidiaries throughout the U.S. and in international markets, the company provide a diversified range of banking and nonbank financial services and products through four business segments: Consumer Banking, Global Wealth & Investment Management (GWIM), Global Banking and Global Markets, with the remaining operations recorded in All Other. The company operate its banking activities primarily under the Bank of America, National Association (Bank of America, N.A. or BANA) charter. At March 31, 2018, the Corporation had a...
2018-06-18 - Asif
Business Arrowhead develops medicines that treat intractable diseases by silencing the genes that cause them. Using a broad portfolio of RNA chemistries and efficient modes of delivery, Arrowhead therapies trigger the RNA interference mechanism to induce rapid, deep and durable knockdown of target genes. RNA interference, or RNAi, is a mechanism present in living cells that inhibits the expression of a specific gene, thereby affecting the production of a specific protein. Deemed to be one of the most important recent discoveries in life science with the potential to transform medicine, the discoverers of RNAi were awarded a Nobel Prize in 2006 for their work. Arrowhead’s RNAi-based therapeutics leverage this natural pathway of gene silencing. In fiscal 2017, Arrowhead refocused its resources on therapeutics that exclusively utilize the company’s Targeted RNAi Molecule (TRiMTM) platform technology. Therapeutics built on the TRiMTM platform have demonstrated high levels of pha...
as of ET